IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v415y2002i6869d10.1038_415331a.html
   My bibliography  Save this article

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Author

Listed:
  • John W. Shiver

    (Merck Research Laboratories)

  • Tong-Ming Fu

    (Merck Research Laboratories)

  • Ling Chen

    (Merck Research Laboratories)

  • Danilo R. Casimiro

    (Merck Research Laboratories)

  • Mary-Ellen Davies

    (Merck Research Laboratories)

  • Robert K. Evans

    (Merck Research Laboratories)

  • Zhi-Qiang Zhang

    (Merck Research Laboratories)

  • Adam J. Simon

    (Merck Research Laboratories)

  • Wendy L. Trigona

    (Merck Research Laboratories)

  • Sheri A. Dubey

    (Merck Research Laboratories)

  • Lingyi Huang

    (Merck Research Laboratories)

  • Virginia A. Harris

    (Merck Research Laboratories)

  • Romnie S. Long

    (Merck Research Laboratories)

  • Xiaoping Liang

    (Merck Research Laboratories)

  • Larry Handt

    (Merck Research Laboratories)

  • William A. Schleif

    (Merck Research Laboratories)

  • Lan Zhu

    (Merck Research Laboratories)

  • Daniel C. Freed

    (Merck Research Laboratories)

  • Natasha V. Persaud

    (Merck Research Laboratories)

  • Liming Guan

    (Merck Research Laboratories)

  • Kara S. Punt

    (Merck Research Laboratories)

  • Aimin Tang

    (Merck Research Laboratories)

  • Minchun Chen

    (Merck Research Laboratories)

  • Keith A. Wilson

    (Merck Research Laboratories)

  • Kelly B. Collins

    (Merck Research Laboratories)

  • Gwendolyn J. Heidecker

    (Merck Research Laboratories)

  • V. Rose Fernandez

    (Merck Research Laboratories)

  • Helen C. Perry

    (Merck Research Laboratories)

  • Joseph G. Joyce

    (Merck Research Laboratories)

  • Karen M. Grimm

    (Merck Research Laboratories)

  • James C. Cook

    (Merck Research Laboratories)

  • Paul M. Keller

    (Merck Research Laboratories)

  • Denise S. Kresock

    (Merck Research Laboratories)

  • Henryk Mach

    (Merck Research Laboratories)

  • Robert D. Troutman

    (Merck Research Laboratories)

  • Lynne A. Isopi

    (Merck Research Laboratories)

  • Donna M. Williams

    (Merck Research Laboratories)

  • Zheng Xu

    (Merck Research Laboratories)

  • Kathryn E. Bohannon

    (Merck Research Laboratories)

  • David B. Volkin

    (Merck Research Laboratories)

  • David C. Montefiori

    (Center for AIDS Research, Duke University Medical Center)

  • Ayako Miura

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Georgia R. Krivulka

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Michelle A. Lifton

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Marcelo J. Kuroda

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Jörn E. Schmitz

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Norman L. Letvin

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Michael J. Caulfield

    (Merck Research Laboratories)

  • Andrew J. Bett

    (Merck Research Laboratories)

  • Rima Youil

    (Merck Research Laboratories)

  • David C. Kaslow

    (Merck Research Laboratories)

  • Emilio A. Emini

    (Merck Research Laboratories)

Abstract

Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of simian immunodeficiency virus (SIV) in rhesus monkeys have shown that resolution of the acute viral infection and control of the subsequent persistent infection are mediated by the antiviral cellular immune response1,2,3,4,5,6,7,8,9,10,11. We comparatively assessed several vaccine vector delivery systems—three formulations of a plasmid DNA vector, the modified vaccinia Ankara (MVA) virus, and a replication incompetent adenovirus type 5 (Ad5) vector—expressing the SIV gag protein for their ability to elicit such immune responses in monkeys. The vaccines were tested either as a single modality or in combined modality regimens. Here we show that the most effective responses were elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector. After challenge with a pathogenic HIV–SIV hybrid virus (SHIV), the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the virus infection. The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine.

Suggested Citation

  • John W. Shiver & Tong-Ming Fu & Ling Chen & Danilo R. Casimiro & Mary-Ellen Davies & Robert K. Evans & Zhi-Qiang Zhang & Adam J. Simon & Wendy L. Trigona & Sheri A. Dubey & Lingyi Huang & Virginia A. , 2002. "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity," Nature, Nature, vol. 415(6869), pages 331-335, January.
    • Handle: RePEc:nat:nature:v:415:y:2002:i:6869:d:10.1038_415331a
    DOI: 10.1038/415331a
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/415331a
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/415331a?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:415:y:2002:i:6869:d:10.1038_415331a. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.